© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer
Affiliations of authors: Cancer Research UK, Department of Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary College, University of London, London, U.K. (JC, JW, EP, SWD); Cambridge Breast Unit, Addenbrookes Hospital, Cambridge, U.K. (RMLW)
Correspondence to: Jack Cuzick, PhD, Cancer Research UK, Department of Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Charterhouse Square, London, EC1M 6BQ, U.K. (e-mail: jack.cuzick{at}cancer.org.uk)
Background: Although mammographic breast density is associated with the risk of breast cancer and is influenced by hormone levels, the effects of tamoxifen on breast density in healthy women and whether tamoxifen-induced density changes are associated with breast cancer risk are unclear. We investigated mammographic breast density in healthy women with an increased risk of breast cancer at baseline and during 54 months of tamoxifen treatment. Methods: Mammograms were reviewed from 818 breast cancerfree women (388 in the tamoxifen group and 430 in the placebo group) at high risk for breast cancer, from the International Breast Cancer Intervention Study I, a trial of tamoxifen for breast cancer prevention. Breast density measurements, at baseline and during treatment, were obtained at 12- to 18-month intervals. Multivariable analysis was used to assess associations with breast density. All statistical tests were two-sided. Results: Breast density at baseline was similar in placebo (42.6%, 95% confidence interval [CI] = 39.6% to 45.6%) and tamoxifen (41.9%, 95% CI = 38.8% to 45.0%) groups. The main determinants of breast density at baseline were age, menopausal status, body mass index, and previous atypical hyperplasia. A greater density reduction in the tamoxifen group (7.9%, 95% CI = 6.9% to 8.9%) than in the placebo group (3.5%, 95% CI = 2.7% to 4.3%) was apparent within 18 months of treatment (P<.001); the reduction in density continued until 54 months of treatment. After 54 months of tamoxifen treatment, breast density was 28.2% (decrease from baseline = 13.7%, 95% CI = 12.3% to 15.1%; P<.001) in the tamoxifen group and 35.3% (decrease from baseline = 7.3%, 95% CI = 6.1% to 8.4%; P<.001) in the placebo group. The tamoxifen-associated density reduction was apparent in all subgroups, but there was a statistically significant interaction with age. In women aged 45 years or younger at entry, the net reduction with tamoxifen was 13.4% (95% CI = 8.6% to 18.1%), whereas in women older than 55 years, it was 1.1% (95% CI = 3.0% to 5.1%). Conclusion: Tamoxifen treatment was associated with reduction in breast density, most of which occurred during the first 18 months of treatment.
This article has been cited by other articles:
![]() |
S. Berube, C. Diorio, and J. Brisson Multivitamin-multimineral supplement use and mammographic breast density Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1400 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ding, R. Warren, I. Warsi, N. Day, D. Thompson, M. Brady, C. Tromans, R. Highnam, and D. Easton Evaluating the Effectiveness of Using Standard Mammogram Form to Predict Breast Cancer Risk: Case-Control Study Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1074 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Kelemen, V. S. Pankratz, T. A. Sellers, K. R. Brandt, A. Wang, C. Janney, Z. S. Fredericksen, J. R. Cerhan, and C. M. Vachon Age-specific Trends in Mammographic Density: The Minnesota Breast Cancer Family Study Am. J. Epidemiol., May 1, 2008; 167(9): 1027 - 1036. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Peters, U. Ekelund, M. Leitzmann, D. Easton, R. Warren, R. Luben, S. Bingham, K.-T. Khaw, and N. J. Wareham Physical Activity and Mammographic Breast Density in the EPIC-Norfolk Cohort Study Am. J. Epidemiol., March 1, 2008; 167(5): 579 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al. Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian Low-Dose Tamoxifen for Combination Hormone Replacement Therapy Users J. Clin. Oncol., September 20, 2007; 25(27): 4162 - 4164. [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, T. A. Sellers, E. E. Carlson, J. M. Cunningham, C. A. Hilker, R. L. Smalley, D. J. Schaid, L. E. Kelemen, F. J. Couch, and V. S. Pankratz Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer Cancer Res., September 1, 2007; 67(17): 8412 - 8418. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Tamimi, C. Byrne, G. A. Colditz, and S. E. Hankinson Endogenous Hormone Levels, Mammographic Density, and Subsequent Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, August 1, 2007; 99(15): 1178 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, V. S. Pankratz, C. G. Scott, S. D. Maloney, K. Ghosh, K. R. Brandt, T. Milanese, M. J. Carston, and T. A. Sellers Longitudinal Trends in Mammographic Percent Density and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 921 - 928. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Irwin, E. J. Aiello, A. McTiernan, L. Bernstein, F. D. Gilliland, R. N. Baumgartner, K. B. Baumgartner, and R. Ballard-Barbash Physical Activity, Body Mass Index, and Mammographic Density in Postmenopausal Breast Cancer Survivors J. Clin. Oncol., March 20, 2007; 25(9): 1061 - 1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, L. Ichikawa, D. L. Miglioretti, D. S. M. Buist, P. M. Vacek, R. Smith-Bindman, B. Yankaskas, P. A. Carney, and R. Ballard-Barbash Longitudinal Measurement of Clinical Mammographic Breast Density to Improve Estimation of Breast Cancer Risk J Natl Cancer Inst, March 7, 2007; 99(5): 386 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Weitzel, S. S. Buys, W. H. Sherman, A. M. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, M. C. Pike, and D. V. Spicer Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers Clin. Cancer Res., January 15, 2007; 13(2): 654 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, K. R. Brandt, K. Ghosh, C. G. Scott, S. D. Maloney, M. J. Carston, V. S. Pankratz, and T. A. Sellers Mammographic Breast Density as a General Marker of Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 43 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Boyd, L. J. Martin, L. Sun, H. Guo, A. Chiarelli, G. Hislop, M. Yaffe, and S. Minkin Body Size, Mammographic Density, and Breast Cancer Risk. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2086 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian and B. F. Kimler Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials J. Nutr., October 1, 2006; 136(10): 2705S - 2708S. [Full Text] [PDF] |
||||
![]() |
R. Warren, J. Skinner, E. Sala, E. Denton, M. Dowsett, E. Folkerd, C. S. Healey, A. Dunning, D. Doody, B. Ponder, et al. Associations among Mammographic Density, Circulating Sex Hormones, and Polymorphisms in Sex Hormone Metabolism Genes in Postmenopausal Women. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1502 - 1508. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Palomares, J. R.B. Machia, C. D. Lehman, J. R. Daling, and A. McTiernan Mammographic density correlation with gail model breast cancer risk estimates and component risk factors. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1324 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. McCormack and I. dos Santos Silva Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1159 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Boyd, L. J. Martin, Q. Li, L. Sun, A. M. Chiarelli, G. Hislop, M. J. Yaffe, and S. Minkin Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 961 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, et al. Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women J. Clin. Oncol., January 1, 2006; 24(1): 129 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Tamimi, S. E. Hankinson, G. A. Colditz, and C. Byrne Endogenous Sex Hormone Levels and Mammographic Density among Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2641 - 2647. [Abstract] [Full Text] [PDF] |
||||
![]() |
M K Simick and L Lilge Optical transillumination spectroscopy to quantify parenchymal tissue density: an indicator for breast cancer risk Br. J. Radiol., November 1, 2005; 78(935): 1009 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. McTiernan, C. F. Martin, J. D. Peck, A. K. Aragaki, R. T. Chlebowski, E. D. Pisano, C. Y. Wang, R. L. Brunner, K. C. Johnson, J. E. Manson, et al. Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial J Natl Cancer Inst, September 21, 2005; 97(18): 1366 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Dite, J. D. Wark, G. G. Giles, D. R. English, M. R.E. McCredie, and J. L. Hopper Is There Overlap Between the Genetic Determinants of Mammographic Density and Bone Mineral Density? Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2266 - 2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Berube, C. Diorio, B. Masse, N. Hebert-Croteau, C. Byrne, G. Cote, M. Pollak, M. Yaffe, and J. Brisson Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF] |
||||
![]() |
K. Kerlikowske, J. Shepherd, J. Creasman, J. A. Tice, E. Ziv, and S. R. Cummings Are Breast Density and Bone Mineral Density Independent Risk Factors for Breast Cancer? J Natl Cancer Inst, March 2, 2005; 97(5): 368 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ziv, J. Tice, R. Smith-Bindman, J. Shepherd, S. Cummings, and K. Kerlikowske Mammographic Density and Estrogen Receptor Status of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2090 - 2095. [Abstract] [Full Text] [PDF] |
||||









